Long- vs Short-Course Radiation Therapy in Rectal Cancer

Video

This video reviews some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.

In this video, Chi Lin, MD, PhD, of the University of Nebraska Medical Center, discusses some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.

Lin gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Related Content
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

Tim Cortese
June 17th 2025
Article

A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

Roman Fabbricatore
June 13th 2025
Article

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

Roman Fabbricatore
June 11th 2025
Article

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

Russ Conroy
June 10th 2025
Article

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.